Lacnotuzumab clinical trials
Also written MCS110.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses lacnotuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MCS110
- 7
Studies by the year they started
8 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 3
Novartis Pharmaceuticals (5) · Dana-Farber Cancer Institute (1) · Seoul National University Hospital (1) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Spartalizumab (2) · Adenosine A2A Receptor Antagonist NIR178 (1)
Studies
Open first, then newest update. How each study uses lacnotuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).TerminatedPhase 1Novartis PharmaceuticalsNCT03742349Written as MCS110
- MCS110 With BRAF/MEK Inhibition in Patients With MelanomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT03455764Written as MCS110
- Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesCompletedPhase 1/2Novartis PharmaceuticalsNCT02807844Written as MCS110
- Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)CompletedPhase 2Novartis PharmaceuticalsNCT02435680Written as MCS110
- MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)CompletedPhase 2Novartis PharmaceuticalsNCT01643850Written as MCS110
- A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone MetastasesTerminatedPhase 1/2Novartis PharmaceuticalsNCT00757757Written as MCS110
- Biomarker Study of PDR001 in Combination With MCS110 in Gastric CancerStatus unknownPhase 2Seoul National University HospitalNCT03694977Written as MCS110/PDR001 combination
- MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast CancerWithdrawnPhase 1Washington University School of MedicineNCT03285607Written as MCS110
Codes
What other systems call lacnotuzumab · ClinicalTrials.gg INT015418
- UNII (FDA) 77624NN1TULACNOTUZUMABOne source FDA
- NCI Thesaurus C80044LacnotuzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 77624NN1TU | LACNOTUZUMAB | One source FDA |
| NCI Thesaurus | C80044 | Lacnotuzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.